SPARC Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Sun Pharma Advanced Research Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹204.50 |
| 52 Week High | ₹472.80 |
| 52 Week Low | ₹189.75 |
| Beta | 0.83 |
| 11 Month Change | -0.48% |
| 3 Month Change | -12.10% |
| 1 Year Change | -25.11% |
| 33 Year Change | -18.96% |
| 5 Year Change | 26.31% |
| Change since IPO | 134.52% |
Recent News & Updates
Recent updates
Sun Pharma Advanced Research (NSE:SPARC) Is In A Good Position To Deliver On Growth Plans
Jan 17
Sun Pharma Advanced Research Company Limited's (NSE:SPARC) Business Is Trailing The Industry But Its Shares Aren't
Nov 14Is Sun Pharma Advanced Research (NSE:SPARC) Using Too Much Debt?
Sep 05Here's Why We're Not At All Concerned With Sun Pharma Advanced Research's (NSE:SPARC) Cash Burn Situation
Jun 27Is Sun Pharma Advanced Research (NSE:SPARC) A Risky Investment?
Nov 23If You Had Bought Sun Pharma Advanced Research's (NSE:SPARC) Shares Three Years Ago You Would Be Down 57%
Feb 08
Do Institutions Own Sun Pharma Advanced Research Company Limited (NSE:SPARC) Shares?
Dec 14Shareholder Returns
| SPARC | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.6% | 0.5% | 0.5% |
| 1Y | -25.1% | 42.5% | 27.5% |
Return vs Industry: SPARC underperformed the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: SPARC underperformed the Indian Market which returned 27.5% over the past year.
Price Volatility
| SPARC volatility | |
|---|---|
| SPARC Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: SPARC has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SPARC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 409 | Anilkumar Raghavan | www.sparc.life |
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company’s products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures.
Sun Pharma Advanced Research Company Limited Fundamentals Summary
| SPARC fundamental statistics | |
|---|---|
| Market cap | ₹66.36b |
| Earnings (TTM) | -₹4.09b |
| Revenue (TTM) | ₹600.85m |
110.5x
P/S Ratio-16.2x
P/E RatioIs SPARC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPARC income statement (TTM) | |
|---|---|
| Revenue | ₹600.85m |
| Cost of Revenue | ₹376.39m |
| Gross Profit | ₹224.47m |
| Other Expenses | ₹4.31b |
| Earnings | -₹4.09b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -12.59 |
| Gross Margin | 37.36% |
| Net Profit Margin | -680.16% |
| Debt/Equity Ratio | -114.7% |
How did SPARC perform over the long term?
See historical performance and comparison